Diabetic Nephropathy Market

• Rising Prevalence of Diabetic Patients to Boost the Market Growth

There are numerous symptoms of diabetic nephropathy, but the most common is diabetes mellitus. End-stage renal failure is 10 times more common in people with diabetes mellitus. For instance, International Diabetes Federation 2022 estimates that diabetes was a cause of 6.7 million fatalities in 2021. Along with that, 1 in 10 individuals (20 to 79 years old) have diabetes, which affects 537 million people. By 2030, it is expected to reach 643 million, and by 2045, it will reach 783 million. Similarly, according to the International Diabetes Federation (IDF), 40% of diabetics may experience kidney failure in its ultimate stages.

Furthermore, about 80% of end-stage renal failure is caused by diabetes and hypertension, either together or individually.

The introduction of new medicine for diabetic nephropathy in developing nations and the drug approvals by the FDA is offering a remunerative opportunity to the market. Due to an increase in both temporary and permanent chronic heart disease, hypertensive heart attacks, and diabetic nephropathy, angiotensin-converting enzyme inhibitors are frequently utilized. Thus, it stimulates market expansion.

The aging global population is contributing to the expansion of the Global Diabetic Nephropathy Market Industry. As individuals age, the risk of developing chronic conditions, including diabetes and its complications, increases. The United Nations projects that by 2050, the number of people aged 60 years and older will double, reaching approximately 2.1 billion. This demographic shift is expected to result in a higher incidence of diabetic nephropathy, as older adults are more susceptible to kidney disease. Consequently, healthcare systems will need to adapt to this growing demand for nephropathy management, further propelling market growth.

The Global Diabetic Nephropathy Market Industry is poised for substantial growth, with projections indicating an increase from 2.49 USD Billion in 2024 to 5.15 USD Billion by 2035. This growth trajectory reflects a compound annual growth rate (CAGR) of 6.82% from 2025 to 2035. The market dynamics are influenced by various factors, including the rising prevalence of diabetes, advancements in treatment options, and increased awareness regarding kidney health. As these elements converge, the market is likely to witness significant developments, shaping the future landscape of diabetic nephropathy management.

The increasing prevalence of diabetes globally serves as a primary driver for the Global Diabetic Nephropathy Market Industry. According to the World Health Organization, the number of individuals diagnosed with diabetes has risen significantly, with estimates suggesting that by 2030, approximately 578 million people will be affected. This growing diabetic population is likely to lead to a corresponding rise in diabetic nephropathy cases, as diabetes is a leading cause of chronic kidney disease. Consequently, the demand for effective treatments and management strategies is expected to surge, contributing to the market's projected growth from 2.49 USD Billion in 2024 to 5.15 USD Billion by 2035.

Support from regulatory bodies and increased funding for diabetes-related research are bolstering the Global Diabetic Nephropathy Market Industry. Governments and health organizations are recognizing the need for enhanced research and development in diabetic nephropathy treatments. Initiatives such as the National Institutes of Health's funding for kidney disease research are indicative of this trend. Such support not only encourages innovation but also facilitates the development of new therapies and management strategies, ultimately contributing to the market's expansion as more effective solutions become available.

Innovations in treatment modalities for diabetic nephropathy are propelling the Global Diabetic Nephropathy Market Industry forward. Recent developments in pharmacotherapy, including the introduction of SGLT2 inhibitors and GLP-1 receptor agonists, have shown promise in delaying the progression of kidney disease in diabetic patients. These advancements not only improve patient outcomes but also enhance the quality of life for those affected. As healthcare providers increasingly adopt these novel therapies, the market is likely to experience substantial growth, with a compound annual growth rate (CAGR) of 6.82% projected from 2025 to 2035, reflecting the ongoing commitment to improving diabetic nephropathy management.

Heightened awareness regarding diabetic nephropathy and its complications is fostering growth in the Global Diabetic Nephropathy Market Industry. Public health campaigns and educational initiatives aimed at both healthcare professionals and patients are emphasizing the importance of early detection and management of kidney disease. For instance, organizations such as the National Kidney Foundation are actively promoting screening for kidney function in diabetic patients. This increased awareness is likely to lead to earlier diagnosis and intervention, thereby expanding the patient base requiring treatment and management solutions, ultimately driving market growth.

By region, the study segments the market into North America, Europe, Asia-Pacific, and the Rest of the World. North America diabetic nephropathy held the largest market share in 2022. This is attributed to the increase in the prevalence of diabetic nephropathy, health care infrastructure, and increased use of combination drugs, as well as an increase in diabetic patients’ awareness of diabetic nephropathy.

Further, the major countries studied are: The U.S, Canada, Germany, France, UK, Italy, Spain, China, Japan, India, Australia, South Korea, and Brazil.

Figure 3: Diabetic Nephropathy Market Share (%) By Region 2022

Source: Secondary Research, Primary Research, Market Research Future Database and Analyst Review

Europe diabetic nephropathy market accounts for the second-largest market share due to the rising government and pharmaceutical organization efforts to raise awareness of kidney disease as well as the existence of generic manufacturers are also boosting the market growth. Further, the Germany diabetic nephropathy market held the largest market share, and the UK diabetic nephropathy market was the fastest-growing market in the European region.

The Asia-Pacific Diabetic Nephropathy market is expected to grow at a significant growth rate during the forecast period. This is due to the increased healthcare spending, increased market awareness of new diabetic drugs, and increase in the number of hospitals are factors expected to boost the market over the forecast period. Moreover, China diabetic nephropathy market held the largest market share, and the India diabetic nephropathy market was the fastest-growing market in the Asia-Pacific region. Hence, Asia-Pacific is anticipated to register the highest growth rate over the forecast period from 2024–2032.

Major market players are spending a lot of money on R&D to increase their product lines, which will help the diabetic nephropathy market grow even more. Market participants are also taking a range of strategic initiatives to grow their worldwide footprint, including new product launches, contractual agreements, mergers and acquisitions, increased investments, and collaboration with other organizations. Competitors in the diabetic nephropathy industry must offer cost-effective items to expand and survive in an increasingly competitive and rising market environment.

One of the primary business strategies adopted by manufacturers in the diabetic nephropathy industry to benefit clients and expand the diabetic nephropathy market sector is to manufacture locally to reduce operating costs.

AstraZeneca (UK) is a leading biopharmaceutical company. It focuses on developing and commercializing prescribed medicines. It has three main therapy areas, namely, cardiovascular, and metabolic disease (CVMD), oncology, and respiratory. It is also active in areas such as neuroscience autoimmunity and infection. Their product portfolio includes medications in the field of oncology, cardiovascular, renal & metabolism, and respiratory diseases, among others.

For instance, in 2021, AstraZeneca’s Farxiga (dapagliflozin), a sodium-glucose cotransporter 2 (SGLT2) inhibitor, has been approved in the US to reduce the risk of sustained estimated glomerular filtration rate (eGFR) decline, end-stage kidney disease (ESKD), cardiovascular (CV) death and hospitalization for heart failure (hHF) in adults with chronic kidney disease (CKD) at risk of progression.